There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Rocket Pharmaceuticals (RCKT – Research Report), Arcutis Biotherapeutics (ARQT – Research Report) and Genenta Science SpA Sponsored ADR (GNTA – Research Report) with bullish sentiments.
Rocket Pharmaceuticals (RCKT)
In a report released yesterday, Michael Ulz from Morgan Stanley maintained a Buy rating on Rocket Pharmaceuticals, with a price target of $45.00. The company’s shares closed last Wednesday at $20.17.
According to TipRanks.com, Ulz is a 2-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Rocket Pharmaceuticals with a $49.50 average price target, which is a 138.0% upside from current levels. In a report issued on January 23, SVB Securities also maintained a Buy rating on the stock with a $49.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Arcutis Biotherapeutics (ARQT)
In a report released today, Uy Ear from Mizuho Securities reiterated a Buy rating on Arcutis Biotherapeutics, with a price target of $61.00. The company’s shares closed last Wednesday at $16.50.
According to TipRanks.com, Ear is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arcutis Biotherapeutics with a $52.50 average price target.
Genenta Science SpA Sponsored ADR (GNTA)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Genenta Science SpA Sponsored ADR yesterday and set a price target of $21.00. The company’s shares closed last Wednesday at $6.28.
According to TipRanks.com, McCarthy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Genenta Science SpA Sponsored ADR is a Strong Buy with an average price target of $20.33, representing a 238.8% upside. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $25.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RCKT:
- Rocket Pharmaceuticals announces RMAT designation for RP-A501 from FDA
- Rocket Pharmaceuticals initiated with an Overweight at Morgan Stanley
- Rocket Pharmaceuticals adds RP-A601, PKP2-ACM to gene therapy portfolio
- Rocket Pharmaceuticals stock reaction looks ‘overdone,’ says BofA
- William Blair remains bullish on Rocket following FDA discussion commentary
